YU48038B - PROCEDURE FOR DIAGNOSIS OF NO-A, NO-V HEPATITIS - Google Patents

PROCEDURE FOR DIAGNOSIS OF NO-A, NO-V HEPATITIS

Info

Publication number
YU48038B
YU48038B YU213888A YU213888A YU48038B YU 48038 B YU48038 B YU 48038B YU 213888 A YU213888 A YU 213888A YU 213888 A YU213888 A YU 213888A YU 48038 B YU48038 B YU 48038B
Authority
YU
Yugoslavia
Prior art keywords
hepatitis
genome
diagnosis
procedure
polyprotein
Prior art date
Application number
YU213888A
Other languages
Serbo-Croatian (sh)
Other versions
YU213888A (en
Inventor
M. Houghton
Q.L. Choo
G. Kuo
Original Assignee
Chiron Corp.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27537644&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=YU48038(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chiron Corp. filed Critical Chiron Corp.
Priority to SI8812138A priority Critical patent/SI8812138B/en
Publication of YU213888A publication Critical patent/YU213888A/en
Priority to HR940493A priority patent/HRP940493B1/en
Publication of YU48038B publication Critical patent/YU48038B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/706—Specific hybridization probes for hepatitis
    • C12Q1/707—Specific hybridization probes for hepatitis non-A, non-B Hepatitis, excluding hepatitis D
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • G01N33/5767—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis non-A, non-B hepatitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

POSTUPAK ZA DIJAGNOSTIKU NE-A, NE-V HEPATITISA - polipeptid u izolovanom obliku koji obuhvata graničnu sekvencu od bar 10 amino kiselina kodiranih pomoću genoma hepatitis C virusa (HCV) i koji obuhvata antigenski determinant, gde je i) pozitivno navijenog RNA genoma; ii) pomenutog genoma koji obuhvata otvoren čitajući ram (ORF) koji kodira poliprotein; i iii) pomenutog poliproteina koji obuhvata amino kiselinsku sekvencu koja ima bar 40 % homologije prema 859 amino kiselinskoj sekvenci na sl. 14 Prijava sadrži još 5 nezavisnih i 58 zavisnih zahteva.PROCEDURE FOR DIAGNOSIS OF NE-A, NE-V HEPATITIS - an isolated polypeptide comprising a boundary sequence of at least 10 amino acids encoded by the hepatitis C virus (HCV) genome and comprising an antigenic determinant, wherein i) is a positively coiled RNA genome; ii) said genome comprising an open reading frame (ORF) encoding a polyprotein; and iii) said polyprotein comprising an amino acid sequence having at least 40% homology to the 859 amino acid sequence of FIG. 14 The application contains 5 more independent and 58 dependent requests.

YU213888A 1987-11-18 1988-11-18 PROCEDURE FOR DIAGNOSIS OF NO-A, NO-V HEPATITIS YU48038B (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
SI8812138A SI8812138B (en) 1987-11-18 1988-11-18 Nanbv diagnostics and vaccines
HR940493A HRP940493B1 (en) 1987-11-18 1994-09-07 Nanbv diagnostics and vaccines

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US12271487A 1987-11-18 1987-11-18
US13988687A 1987-12-30 1987-12-30
US16107288A 1988-02-26 1988-02-26
US19126388A 1988-05-06 1988-05-06
US26358488A 1988-10-26 1988-10-26

Publications (2)

Publication Number Publication Date
YU213888A YU213888A (en) 1991-02-28
YU48038B true YU48038B (en) 1996-10-18

Family

ID=27537644

Family Applications (1)

Application Number Title Priority Date Filing Date
YU213888A YU48038B (en) 1987-11-18 1988-11-18 PROCEDURE FOR DIAGNOSIS OF NO-A, NO-V HEPATITIS

Country Status (3)

Country Link
GB (1) GB2212511B (en)
SG (1) SG102092G (en)
YU (1) YU48038B (en)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5683864A (en) * 1987-11-18 1997-11-04 Chiron Corporation Combinations of hepatitis C virus (HCV) antigens for use in immunoassays for anti-HCV antibodies
US5712088A (en) * 1987-11-18 1998-01-27 Chiron Corporation Methods for detecting Hepatitis C virus using polynucleotides specific for same
US6171782B1 (en) 1987-11-18 2001-01-09 Chiron Corporation Antibody compositions to HCV and uses thereof
US5350671A (en) * 1987-11-18 1994-09-27 Chiron Corporation HCV immunoassays employing C domain antigens
US6861212B1 (en) 1987-11-18 2005-03-01 Chiron Corporation NANBV diagnostics and vaccines
US5698390A (en) * 1987-11-18 1997-12-16 Chiron Corporation Hepatitis C immunoassays
US5714596A (en) * 1987-11-18 1998-02-03 Chiron Corporation NANBV diagnostics: polynucleotides useful for screening for hepatitis C virus
US6027729A (en) * 1989-04-20 2000-02-22 Chiron Corporation NANBV Diagnostics and vaccines
NO905438L (en) 1989-12-18 1991-06-19 Wellcome Found VIRUS AGENT.
US7166287B1 (en) 1989-12-18 2007-01-23 Glaxo Wellcome Inc. Viral agent
US6312889B1 (en) 1990-04-04 2001-11-06 Chiron Corporation Combinations of hepatitis c virus (HCV) antigens for use in immunoassays for anti-HCV antibodies
US6194140B1 (en) * 1990-04-04 2001-02-27 Chiron Corporation HCV NS3 protein fragments having helicase activity and improved solubility
US6172189B1 (en) * 1990-08-24 2001-01-09 Abbott Laboratories Hepatitis C assay utilizing recombinant antigens
ES2098511T3 (en) * 1991-03-26 1997-05-01 Dade Int Inc DIAGNOSIS PROCEDURE FOR HEPATITIS NO-A NO-B.
US5574132A (en) * 1991-04-05 1996-11-12 Biochem Immunosystems Inc. Peptides and mixtures thereof for detecting antibodies to hepatitis C virus (HCV)
RO117329B1 (en) * 1991-06-24 2002-01-30 Chiron Corp Emeryville Polypeptides containing a hcv sequence
CA2129733C (en) * 1992-01-31 2006-10-31 James M. Casey Mammalian expression systems for hcv proteins
US6620414B2 (en) 1992-03-27 2003-09-16 Smithkline Beecham Biologicals (S.A.) Hepatitis vaccines containing 3-0-deacylated monophoshoryl lipid A
US5514539A (en) * 1993-06-29 1996-05-07 The United States Of America As Represented By The Department Of Health And Human Services Nucleotide and deduced amino acid sequences of the envelope 1 gene of 51 isolates of hepatitis C virus and the use of reagents derived from these sequences in diagnostic methods and vaccines
US7070790B1 (en) 1993-06-29 2006-07-04 The United States Of America As Represented By The Department Of Health And Human Services Nucleotide and deduced amino acid sequences of the envelope 1 and core genes of isolates of hepatitis C virus and the use of reagents derived from these sequences in diagnostic methods and vaccines
US5610009A (en) * 1994-01-28 1997-03-11 Abbott Laboratories Mammalian expression systems for hepatitis C virus envelope genes
EP1211315A1 (en) * 1994-07-29 2002-06-05 Innogenetics N.V. Recombinant vectors for producing HCV envelope proteins
US6107027A (en) * 1994-12-14 2000-08-22 University Of Washington Ribozymes for treating hepatitis C
US6127116A (en) 1995-08-29 2000-10-03 Washington University Functional DNA clone for hepatitis C virus (HCV) and uses thereof
US7049428B1 (en) 1998-03-04 2006-05-23 Washington University HCV variants
US7338759B1 (en) 1997-03-04 2008-03-04 Washington University HCV variants
ATE348337T1 (en) * 2000-06-15 2007-01-15 Novartis Vaccines & Diagnostic HCV ANTIGEN/ANTIBODY COMBINATION ASSAY
WO2017004022A2 (en) * 2015-06-29 2017-01-05 The Board Of Trustees Of The Leland Stanford Junior University Degron fusion constructs and methods for controlling protein production
CN107286237B (en) * 2017-08-07 2020-04-03 广州泰诺迪生物科技有限公司 Acquisition and application of anti-hepatitis C virus antibody

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4464474A (en) * 1980-07-09 1984-08-07 Connaught Laboratories Limited Non-A, non-B hepatitis assay and vaccine
GB2108527B (en) * 1981-02-11 1984-10-24 Connaught Lab Non-a non-b hepatitis virus
US4542016A (en) * 1981-03-27 1985-09-17 Institut Merieux Non-a non-b hepatitis surface antigen useful for the preparation of vaccines and methods of use
FR2502154A1 (en) * 1981-03-30 1982-09-24 Trepo Christian PROCESS FOR PREPARING ANTIGENS FOR VIRAL HEPATITIS NANB, AND APPLICATION TO THE REAGENT FOR THE DIAGNOSIS AND PROGNOSIS OF INFECTIONS CAUSED BY VIRAL HEPATITIS VIRUSES
NZ222465A (en) * 1986-11-07 1992-11-25 Pasteur Institut Nanb (non a, non b hepatitis viral) antigen
US4895976A (en) * 1988-05-23 1990-01-23 E. I. Du Pont De Nemours And Company Preparation of 4-pentanoates by isomerization

Also Published As

Publication number Publication date
GB8827024D0 (en) 1988-12-21
GB2212511A (en) 1989-07-26
SG102092G (en) 1992-12-24
YU213888A (en) 1991-02-28
GB2212511B (en) 1992-01-22

Similar Documents

Publication Publication Date Title
YU48038B (en) PROCEDURE FOR DIAGNOSIS OF NO-A, NO-V HEPATITIS
NO904712D0 (en) NANBH DIAGNOSTIC AGENTS AND VACCINES.
ES2012739T5 (en) DIAGNOSTICS FOR NANBV.
DE69433971D1 (en) Epitopes of the virus of C hepatitis immunodominant from human T cells
DK0484787T3 (en) HCV-specific peptides, method of obtaining them and their use
SE9004010A (en) VIRAL MEDICINE
FR2514783B1 (en) HUMAN IMMUNITY INTERFERON
DK0623169T3 (en) Hepatitis E virus and method
DE3582284D1 (en) HEPATITIS-B VACCINE.
KR870000426A (en) Method for preparing compound for synthetic FMDV vaccine
KR880009125A (en) Pancreatic secretive trypsin inhibitors and variants thereof, methods thereof, expression vectors and recombinant hosts and pharmaceutical uses thereof produced by recombinant hosts
KR880000579A (en) Method of producing VeriCella-Joster virus
YU85589A (en) IZRAŽAVANJE HEPATITIS B PRES2 PROTEIN AND METHYLTROFNIM KVASCIMA
JP2001517447A5 (en)
KR900009979A (en) Japanese encephalitis virus non-structural protein production method
KR950000880A (en) Total Nucleotide Sequences and Amino Acid Sequences Inferred from KHCV-L2, a Type of Korean Hepatitis C Virus
IS3511A7 (en) Polypeptides produced by the biotechnology methods, their corresponding nucleic acids, and the use of the polypeptides as a vaccine against VHS virus in fish
KR950000881A (en) Nucleotide Sequences and Amino Acid Sequences Inferred from the New Korean Hepatitis C Virus CDD
TH22297A (en) Diagnosis of NANBV and vaccines
NO306511B1 (en) Recombinant vector that selectively hybridizes to the genome of hepatitis C virus (HCV), a host cell transformed with the vector, and a method for producing a therapeutically active polypeptide
SU1515698A1 (en) Recombinant plasmid dna encoding synthesis of hbs ag hepatitis virus b, and a strain of vaccine virus - a producer of hbs ag hepatitis virus b
TH22297EX (en) Diagnosis of NANBV and vaccines